JPMorgan Chase & Co. to cut sections of Increase Diagnostics (NASDAQ: AXDX) from too much level to unparalleled level in a report published on Wednesday, November 7, MarketBeat.com reports. At this time the stock of a medical research company has a $ 16.00 target, down from the price price; previous $ 25.00.
A number of other research bodies have also commented on AXDX. BidaskClub has increased Diagnostics valued from purchasing level of sales level in a research report on Wednesday, September 5. Zacks Investment Investigation Reduced Diagnostics Evaluation from comparative level to sales rankings in a research report Thursday, August 9. Ultimately, Piper Jaffray's companies made a final decision to repeat and provided a price of $ 24.00 on sections of Experience Acceleration in a research report on Tuesday, 7 August. One research analyst of the stock is evaluated at a retail level, five have given a level of arrest and a man has bought the company. At the moment Hold Accelerate Diagnostics has a consensus rating and a $ 20.25 equation value target.
NASDAQ: AXDX had a $ 0.01 trading transaction during a Wednesday trading, and # 39; hit $ 14.43. A stock of 245,820 shares had a company stock, compared to the average volume of 419,372. The acceleration of Diagnostics is fifty and a half weeks of $ 13.25 and fifty two weeks of $ 30.35. The company currently has a joint assessment of 35.26, a rapid comparison of 33.54 and a debt-equity ratio of 1.52. The company has a market card of $ 770.16 million, in accordance with PE of -12.44 and beta of 2.49.
Expand Diagnostics (NASDAQ: AXDX) finally released its seasonal earning data on Tuesday, November 6. His medical research company ($ 0.41) said the EPS for the season, and # 39; hypothesis Thomson Reuters equation estimation ($ 0.41). Diagnostics Recruitment was negatively negative at 81.76% and negative negative side of 1,365.75%. Its business income was $ 1.36 million for its & # 39; Fourth, compared to analysis estimates of $ 2.89 million. Equalities research investigations acknowledge that Accelerate Diagnostics will be a? post -1.61 earnings per department for the current fiscal year.
In other news on Accelerate Diagnostics, the Director of John Patience purchased 10,000 shares of the company's stock in business dated Thursday 8 November. The shares were purchased at a cost of $ 14.96 per share, for a total trade of $ 149,600.00. After item, the ownership of its & # 39; The company now has 44,670 shares of its company stock, at a value of $ 668,263.20. The matter was published in legal registration by the SEC, which is accessible through this connection. Owners of the company own 49.30% of the stock of the company.
Major funds and other founders have recently bought and sold buy of stock. The Beairteas Clach na Oir Guide found a new position in Acceleration of Trials in the 2nd quarter valued at $ 210,000. SRS Capital Advisors Inc. New situation in Acceleration of Trials in the third quarter worth $ 115,000. HAP Trading LLC received a new post in Acceleration Diagnostics in the third quarter with a value of $ 270,000. Man Group plc received a new post of $ 313,000 in the third quarter of the Appointment of Diagnostics. Eventually, MetLife Investment Advisors LLC raised its case in accelerating Diagnostics with 59.1% in the third quarter. There are 18,052 shares of the medical research company stock at $ 414,000 after buying 6,704 additional shares in the & # 39; last verse. 45.33% of stock is owned by hedge funds and other founding investors.
About A Acceleration of Exams
Accelerate Diagnostics, Inc., is an in vitro diagnostics company, providing solutions for the diagnosis of major diseases in the United States. It offers a fastening Pheno system, an in vitro diagnostic platform for an antibiotic diagnostic test and antibiotics associated with major diseases or disease related to health care, and # 39 ; including gram-positive organisms and negative grams, as well as meat.
See also: what is a debt cost?
Get News & Ratings for Daily Test Acceleration – Enter your email address below to find a daily overview of the latest news and exams for Experience Acceleration and companies related to the current MarketBeat email newsletter. com.